Land: Kanada
Sprache: Englisch
Quelle: Health Canada
OXYBUTYNIN CHLORIDE
JANSSEN INC
G04BD04
OXYBUTYNIN
5MG
TABLET (EXTENDED-RELEASE)
OXYBUTYNIN CHLORIDE 5MG
ORAL
100
Prescription
Antimuscarinics
Active ingredient group (AIG) number: 0114692001; AHFS:
CANCELLED POST MARKET
2022-09-15
_Non-223169 DITROPAN XL - APM_.doc _ _ _ _1 of _26_ _ PRODUCT MONOGRAPH PR DITROPAN XL ® oxybutynin chloride Extended-release Tablets, USP 5 mg and 10 mg Anticholinergic/Antispasmodic Agent Janssen Inc. 19 Green Belt Drive Toronto, Ontario M3C 1L9 www.janssen.com/canada Date of Revision: March 12, 2019 Submission Control No: 223169 All trademarks used under license. © 2019 Janssen Inc. _Non-223169 DITROPAN XL - APM_.doc _ _ _ _2 of _26_ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................6 DRUG INTERACTIONS ..................................................................................................10 DOSAGE AND ADMINISTRATION ..............................................................................11 OVERDOSAGE ................................................................................................................12 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................14 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................14 PART II: SCIENTIFIC INFORMATION ...............................................................................16 PHARMACEUTICAL INFORMATION ..........................................................................16 CLINICAL TRIALS ......................................... Lesen Sie das vollständige Dokument